L-.beta.-dioxolane uridine analogs and methods for treating and
preventing Epstein-Barr virus infections
    2.
    发明授权
    L-.beta.-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections 失效
    L-二氧戊环尿苷类似物和治疗和预防爱泼斯坦 - 巴尔病毒感染的方法

    公开(公告)号:US6022876A

    公开(公告)日:2000-02-08

    申请号:US954922

    申请日:1997-10-21

    CPC分类号: C07D405/04

    摘要: The present invention relates to the discovery that certain .beta.-L-dioxolane nucleoside analogs which contain a uracil base, and preferably, a 5-halosubstituted uracil base, exhibit unexpectedly high activity against Epstein-Barr virus (EBV), Varciella-Zoster virus (VZV) and Herpes Virus 8 (HV-8). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus (viral growth) in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds are useful for treating EBV, VZV and HV-8 infections in humans.

    摘要翻译: 本发明涉及以下发现:含有尿嘧啶碱基,优选5-卤代尿嘧啶碱基的某些β-L-二氧戊环核苷类似物对EB病毒(EBV),金丝雀 - 带状疱疹病毒 VZV)和疱疹病毒8(HV-8)。 特别地,根据本发明的化合物显示出对宿主细胞(即动物或人体组织)的非常低毒性的组合对病毒(病毒生长)的复制的有效抑制。 化合物可用于治疗人类的EBV,VZV和HV-8感染。

    L-nucleosides incorporated into polymeric structure for stabilization of
oligonucleotides
    3.
    发明授权
    L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides 失效
    掺入聚合物结构中的L-核苷用于寡核苷酸的稳定化

    公开(公告)号:US5808040A

    公开(公告)日:1998-09-15

    申请号:US682623

    申请日:1997-01-24

    IPC分类号: C07H19/04 C07H1/00 C07H21/04

    CPC分类号: C07H19/04

    摘要: A method for stabilizing an oligonucleotide by including a .beta.-L-2'-deoxy-2'-fluoro-arabinofuranosyl nucleoside at the 5'-terminus, the 3'-terminus, or in the interior of the oligonucleotide. The oligonucleotide can be used in the modulation of gene expression through a process wherein a synthetic oligonucleotide is hybridized to a complementary nucleic acid sequence to inhibit transcription or replication of DNA or to inhibit translation or processing of RNA.

    摘要翻译: PCT No.PCT / US95 / 01253 Sec。 371日期1997年1月24日 102(e)日期1997年1月24日PCT 1995年1月30日PCT PCT。 公开号WO95 / 20595 日期1995年8月3日一种通过在寡核苷酸的5'端,3'端或内部包含β-2'-2'-脱氧-2'-氟 - 阿拉伯呋喃糖基核苷来稳定寡核苷酸的方法 。 寡核苷酸可以通过其中合成的寡核苷酸与互补核酸序列杂交以抑制DNA的转录或复制或抑制RNA的翻译或加工的方法用于调节基因表达。

    L-&bgr;-dioxolane uridine analogs and their pharmaceutical compositions
    4.
    发明授权
    L-&bgr;-dioxolane uridine analogs and their pharmaceutical compositions 有权
    L-β-二氧戊环尿苷类似物及其药物组合物

    公开(公告)号:US06274589B1

    公开(公告)日:2001-08-14

    申请号:US09363793

    申请日:1999-07-29

    IPC分类号: A61K31505

    CPC分类号: C07D405/04

    摘要: The present invention relates to the discovery that certain &bgr;-L-dioxolane nucleoside analogs which contain a uracil base, and preferably, a 5-halosubstituted uracil base, exhibit unexpectedly high activity against Epstein-Barr virus (EBV), Varciella-Zoster virus (VZV) and Herpes Virus 8 (HV-8). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus (viral growth) in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds are useful for treating EBV, VZV and HV-8 infections in humans.

    摘要翻译: 本发明涉及发现含有尿嘧啶碱基,优选5-卤代尿嘧啶碱的某些β-L-二氧戊环核苷类似物对EB病毒(EBV),金丝雀 - 带状疱疹病毒 VZV)和疱疹病毒8(HV-8)。 特别地,根据本发明的化合物显示出对宿主细胞(即动物或人体组织)的非常低毒性的组合对病毒(病毒生长)的复制的有效抑制。 化合物可用于治疗人类的EBV,VZV和HV-8感染。

    Method for the treatment of psoriasis and genital warts
    7.
    发明授权
    Method for the treatment of psoriasis and genital warts 失效
    治疗牛皮癣和生殖器疣的方法

    公开(公告)号:US06436948B1

    公开(公告)日:2002-08-20

    申请号:US09518206

    申请日:2000-03-03

    IPC分类号: A61K31505

    CPC分类号: A61K31/513

    摘要: The present invention relates to the use of prodrug forms of (−)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine to treat psoriasis, genital warts and other hyperproliferative keratinocyte diseases such as hyperkeratosis, ichthyosis, keratoderma or lichen planus.

    摘要翻译: 本发明涉及( - ) - (2S,4S)-1-(2-羟甲基-1,3-二氧戊环-4-基)胞嘧啶的前体药物形式用于治疗牛皮癣,生殖器疣和其它过度增殖性角化细胞疾病 如角化过度,鱼鳞病,角化病或扁平苔藓。

    Oligonucleotides containing L-nucleosides
    9.
    发明授权
    Oligonucleotides containing L-nucleosides 失效
    含有L-核苷的寡核苷酸

    公开(公告)号:US5753789A

    公开(公告)日:1998-05-19

    申请号:US690350

    申请日:1996-07-26

    CPC分类号: C07H21/00

    摘要: Oligonucleotides that include a 2'-fluoro .beta.-L-arabinofuranosyl nucleoside at the 3'-terminus, the 5'-terminus or in the interior of the oligomer. A preferred nucleoside is 2'-fluoro-5-methyl-.beta.-L-arabinofuranosyluridine (also referred to as L-FMAU). This compound is a potent antiviral agent against HBV and EBV and exhibits low cytotoxicity. Other specific examples of active compounds include N.sub.1 -(2'-deoxy-2'-fluoro-.beta.-L-arabinofuranosyl)-5-ethyluracil, N.sub.1 -(2'-deoxy-2'-fluoro-.beta.-L-arabinofuranosyl)-5-iodocytosine), and N.sub.1 -(2'-deoxy-2'-fluoro-.beta.-L-arabinofuranosyl)-5-iodouracil.

    摘要翻译: 寡核苷酸包括2'-氟β-L-阿拉伯呋喃糖基核苷在3'末端,5'末端或低聚物内部。 优选的核苷是2'-氟-5-甲基-β-L-阿拉伯呋喃糖基尿苷(也称为L-FMAU)。 该化合物是一种针对HBV和EBV的强力抗病毒药物,具有低细胞毒性。 活性化合物的其它具体实例包括N1-(2'-脱氧-2'-氟-β-L-阿拉伯呋喃糖基)-5-乙基尿嘧啶,N1-(2'-脱氧-2'-氟-β-阿拉伯呋喃糖基) -5-碘胞嘧啶)和N1-(2'-脱氧-2'-氟-β-L-阿拉伯呋喃糖基)-5-碘尿嘧啶。